Single-Use Bioreactors Market

# Global Single-Use Bioreactors Market Growth and Trend Forecast 2032 <a class="markup--anchor markup--p-anchor" href="https://www.marketsandata.com/industry-reports/single-use-bioreactors-market" target="_blank" rel="noopener" data-href="https://www.marketsandata.com/industry-reports/single-use-bioreactors-market">Global single-use bioreactors market</a> is projected to witness a CAGR of 18.37% during the forecast period 2025–2032, growing from USD 4,225.72 million in 2024 to USD 16,025.94 million in 2032. The single-use bioreactors market is an important part of the healthcare industry, accounting for a significant market size in the healthcare market. Factors such as reduced risk of contamination, technological advancements, increased adoption among startups and SMEs (small and medium-sized enterprises), and advantages over traditional bioreactors drive the market growth. The disposable bioreactor market is fast-changing as biopharmaceutical companies more and more implement disposable bioreactor systems to improve flexibility, speed, and efficiency in drug development and manufacture. These pre-sterilized, disposable bag and component-based systems pose several advantages over conventional stainless-steel bioreactors, such as lower risk of cross-contamination, removal of cleaning and validation processes, and lower installation and maintenance costs, making them highly suitable for small biotech companies, contract manufacturing organizations, and biotherapeutic and biosimilar manufacturers of personalized medicines. The growth in biologics, vaccines, and cell and gene therapies is driving demand for scalable and modular bioprocessing technologies, with single-use bioreactors facilitating quicker product development cycles and simpler compliance with rigorous regulatory demands. Advances in technology have enhanced the reliability, safety, and material quality of these systems, while continued innovation is meeting extractables, leachable, and batch-to-batch performance consistency concerns. In spite of these advantages, the market is hampered by such challenges as the greater initial cost of production compared to stainless steel systems, the necessity for more standardization among suppliers, and complexities in sterility assurance during assembly and operation. The market for single-use bioreactors in the bioprocessing sector is dedicated to the design, production, and deployment of single-use bioreactor systems for a range of biopharmaceutical and biotechnology uses. These systems reduce the demand for conventional stainless-steel bioreactors by offering effective and affordable solutions for cell culture activities including fermentation, protein expression, and cell growth. Biopharmaceutical firms used versatile technology that brought online response to the pandemic, increasing the requirement for quick mass manufacturing of vaccines against the SARS-CoV-2 virus. Single-use systems witnessed huge demand due to coronavirus and the need for large-scale vaccine manufacturing at a fast pace. This led to the expansion of the single-use bioreactors market post pandemic. In March 2025, “Project Nexus,” a collaboration between the UK government’s UK Innovate scheme and the Centre for Process Innovation Limited with a budget of USD 2.45 million, included Photocentric Ltd, Sartorius AG and Sheffield University. The project’s goal is the creation of sustainable bio-based materials for single use bioprocessing technologies such as bioreactors. It incorporates advanced 3D printing and utilizes biocompatible resins to reduce plastic waste, enhance recyclability, and support circular economic concepts. The project aims to transform bioprocessing through novel materials and sustainable approaches alongside net-zero ambitions. It shifts the paradigm of how bioprocessing is approached within the context of increasing concerns surrounding climate change and the environment, balancing the growth of the biopharmaceutical market with environmental consciousness. Click here : <a class="markup--anchor markup--p-anchor" href="https://www.marketsandata.com/industry-reports/single-use-bioreactors-market" target="_blank" rel="nofollow noopener" data-href="https://www.marketsandata.com/industry-reports/single-use-bioreactors-market">https://www.marketsandata.com/industry-reports/single-use-bioreactors-market</a> <h3 class="graf graf--h3">Single-use Bioreactors Offer Clinical Advantages Over Traditional Bioreactors</h3> Single-use bioreactors are rapidly gaining traction in the biopharmaceutical industry due to the significant clinical and operational benefits they offer over traditional stainless-steel bioreactors. As the demand for biologics, vaccines, cell therapies, and gene therapies increases, manufacturers are seeking flexible, efficient, and contamination-free production systems — making single-use bioreactors an increasingly preferred choice. One of the key advantages of single-use bioreactors is their reduced risk of cross-contamination. Since these systems use disposable bags and components, they eliminate the need for rigorous cleaning and sterilization procedures required in conventional bioreactors. This not only enhances product safety but also ensures compliance with stringent regulatory standards. Additionally, the simplified workflow significantly shortens turnaround time between batches, enabling faster clinical development and accelerating time-to-market for life-saving therapies. Single-use systems also offer operational flexibility, allowing manufacturers to easily scale processes from laboratory research to clinical and small-scale commercial production. Their modular design supports rapid adjustments, making them ideal for multiproduct facilities and environments where frequent changeovers are required. Moreover, the reduced capital investment, lower utility consumption, and minimized maintenance contribute to overall cost efficiency. Clinically, single-use bioreactors support improved reproducibility and process consistency, which are critical for sensitive biologics and advanced therapeutics. Their ability to maintain controlled environments and precise monitoring enhances the quality of cell cultures and final drug products. Driven by these advantages, single-use bioreactors are becoming integral to modern bioprocessing strategies, offering a practical and reliable alternative to traditional systems while supporting innovation in the global biopharmaceutical industry. <h3 class="graf graf--h3">Avoiding Risk of Cross-Contamination and Improving Compliance Facilitate the Market Growth</h3> The growing emphasis on product safety, regulatory compliance, and operational efficiency is significantly driving the adoption of advanced bioprocessing solutions across the pharmaceutical and biotechnology sectors. One of the strongest market drivers is the ability of modern production systems — such as single-use technologies, automated equipment, and closed bioprocessing platforms — to minimize the risk of cross-contamination while ensuring strict regulatory compliance. Traditional stainless-steel systems require extensive cleaning, sterilization, and validation procedures. Any deviation in these processes can lead to contamination, batch failures, or regulatory non-compliance, resulting in operational delays and financial losses. Modern single-use systems eliminate these challenges by using pre-sterilized disposable components, which reduce dependence on manual cleaning and significantly lower contamination risks. This ensures safer and more reliable production of sensitive biologics, vaccines, and cell-based therapies. Furthermore, improved compliance with global regulatory standards — such as those set by the FDA, EMA, and WHO — is becoming a key priority for biopharma companies. Advanced bioprocessing solutions support this by enabling consistent, validated workflows with robust process monitoring and documentation features. Automated data recording, digital tracking, and integrated quality control systems help organizations streamline audits and maintain traceability from development to production. The combination of contamination prevention and enhanced regulatory alignment not only supports higher product quality but also shortens turnaround times, increases manufacturing agility, and lowers operational risks. As biologics and personalized therapies continue to rise, these advantages are expected to further accelerate the adoption of innovative bioprocessing technologies — ultimately fueling strong market growth. The market for single-use bioreactors continues to grow because bioreactors can be used to reduce cross-contamination events when applied in multi-product biologic manufacturing systems. Stainless steel equipment requires thorough cleaning and sterilization procedures that involve significant labor in terms of worker time and subject the process to human errors, which may introduce contaminating substances to the system. One of the examples pointing out this benefit is the application of BioBLU Single-Use Bioreactors by Eppendorf with sealed magnetic drives to avoid microbial contamination and becoming pre-sterilized and thus eliminating cleaning validation entirely. This technology is extensively used across the biopharmaceutical market, enabling the companies to achieve streamlined operations along with high quality products and regulations. Consequently, the increasing demand for single-use systems is transforming manufacturing processes. For instance, In July 2024, Avantor, Inc. launched two new high-performance reagents for gene therapy manufacturing, J.T. Baker Cell Lysis Solution and J.T. Baker Endonuclease. These reagents will improve the process efficiency and reduce the contamination risk. <a class="markup--anchor markup--p-anchor" href="https://www.marketsandata.com/industry-reports/single-use-bioreactors-market/sample-request" target="_blank" rel="noopener" data-href="https://www.marketsandata.com/industry-reports/single-use-bioreactors-market/sample-request">Download Free Sample Report</a> <h3 class="graf graf--h3">Technological Advancements to Advance the Global Single-use Bioreactors Market</h3> Recent substantial technological improvements have led to an increased utilization of single-use bioreactors in biopharmaceutical production. Manufacturers are coming up with new ideas to enhance single-use bioreactor film technologies, designs, stirring motors, and sensor systems. Single-use bioreactors are more effective and efficient for developing cell cultures on a large scale due to such advancements. Improved sensor systems for better process monitoring, control, and improvements in the materials and designs of bioreactor bags can promote cell growth and productivity, including other significant advancements. The AMBR 250 modular, a novel benchtop small bioreactor system for parallel fermentation or cell culture, was launched by Sartorius Stedim Biotech. This system gives bioprocess scientists access to advanced benchtop bioreactor technology for process research by combining a special single-use bioreactor vessel with a flexible system architecture. For instance, in September 2023, Getinge launched the AppliFlex ST GMP, a next-generation single-i bioreactor system that allows bioprocesses to easily move from research in the laboratory to clinical manufacturing. The system is specifically suited for cell and gene therapy processes and mRNA manufacturing, providing scalability and Good Manufacturing Practice (GMP) compliance. In another instance, on March 31, 2025, ABEC, Inc. introduced the Advanced Therapy Bioreactor (ATB), a groundbreaking single-use bioreactor for Advanced Therapy Medicinal Products (ATMPs). Mimicking the human circulatory system, it uses hollow fiber membranes for localized nutrient delivery and waste removal, ensuring optimal cell growth. The ATB offers seamless scalability (0.2L to 10L) and automated, closed-system operation. It demonstrated high cell densities and viabilities for T-cells, CD34+ stem cells, HEK293, and CHO cells. This innovation addresses challenges in advanced therapy manufacturing, accelerating clinical and commercial timelines while maintaining consistent cell culture conditions across all scales. <h3 class="graf graf--h3">Asia-Pacific is Expected to Grow at the Fastest Pace in the Forecast Period</h3> The single-use bioreactor market in Asia-Pacific is anticipated to grow at a high CAGR due to generic medicine manufacturers and recent biosimilar industry players based in the region. It faces commercial pressure to quickly scale up production utilizing disposable technology at reduced prices. Growing population and changing disease patterns are driving the demand for biopharmaceuticals and vaccines throughout Asia. Local companies have opted for single-use solutions to expedite facility construction and accelerate their services in the market. In the second half of 2024, Syngene International Ltd, a global contract research, development, and manufacturing organization (CRDMO), will begin clinical and commercial supply of its recently renovated biologics facility (Unit 3) in Bangalore, India, to clients in the United States and Europe. With two production chambers and five 2KL single-use bioreactors each, the machines have a production capacity of 20KL. About Us: Markets and Data provides a comprehensive/ panoramic understanding of markets at global, regional, and country levels. Examine changing consumer preferences, emerging challenges, underlying trends, and growth prospects to accelerate your business strategies. Contact Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: <a class="markup--anchor markup--p-anchor" href="mailto:info@marketsandata.com" target="_blank" rel="nofollow" data-href="mailto:info@marketsandata.com">info@marketsandata.com</a> Website: <a class="markup--anchor markup--p-anchor" href="https://www.marketsandata.com" target="_blank" rel="nofollow noopener" data-href="https://www.marketsandata.com">https://www.marketsandata.com</a>